The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.
We conducted a pilot study to assess the effect of atorvastatin on HIV replication. Patients with stable HAART-controlled infection interrupted therapy and were randomly assigned to a control group or to start atorvastatin 40 or 80 mg/day. Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4.
Lluita contra la SIDA, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.
Eugènia
E
Negredo
Bonaventura
B
Clotet
Jordi
J
Puig
Núria
N
Pérez-Alvarez
Lidia
L
Ruiz
Joan
J
Romeu
José
J
Moltó
Celestino
C
Rey-Joly
Julià
J
Blanco
D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active; D000069059:Atorvastatin; D002784:Cholesterol / Q000097:blood; D004305:Dose-Response Relationship, Drug; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1 / Q000502:physiology*; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D010865:Pilot Projects; D011758:Pyrroles / Q000008:administration & dosage*; D012367:RNA, Viral / Q000097:blood; D014779:Virus Replication / Q000187:drug effects*
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D012367:RNA, Viral; D002784:Cholesterol; D000069059:Atorvastatin